Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

[Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma].

Fukuoka K, Tanaka F, Tsujimura T, Hashimoto-Tamaoki T, Hasegawa S, Nakano T.

Nihon Eiseigaku Zasshi. 2011 May;66(3):553-7. Japanese.

2.

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.

Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J.

Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272.

PMID:
18154821
3.

Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.

Ferro P, Canessa PA, Battolla E, Dessanti P, Franceschini MC, Chiaffi L, Morabito A, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.

Anticancer Res. 2013 Jun;33(6):2707-13.

PMID:
23749930
4.

Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.

Franceschini MC, Ferro P, Canessa PA, Battolla E, Dessanti P, Valentino A, Casolari L, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.

Anticancer Res. 2014 Dec;34(12):7425-9.

PMID:
25503183
5.

Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.

Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):646-50. doi: 10.1158/1055-9965.EPI-08-0422. Epub 2009 Feb 3.

6.

Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.

Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, Pistillo MP, Roncella S.

Cancer Invest. 2013 Jan;31(1):43-50. doi: 10.3109/07357907.2012.749265. Epub 2012 Dec 18.

PMID:
23249166
7.

[Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma].

Amati M, Tomasetti M, Scartozzi M, Mariotti L, Ciuccarelli M, Valentino M, Governa M, Santarelli L.

G Ital Med Lav Ergon. 2007 Jul-Sep;29(3 Suppl):335-8. Italian.

PMID:
18409713
8.

Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.

Hirayama N, Tabata C, Tabata R, Maeda R, Yasumitsu A, Yamada S, Kuribayashi K, Fukuoka K, Nakano T.

Respir Med. 2011 Jan;105(1):137-42. doi: 10.1016/j.rmed.2010.10.010. Epub 2010 Oct 30.

9.

Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.

Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T.

Clin Chem Lab Med. 2011 Oct;49(10):1721-6. doi: 10.1515/CCLM.2011.242. Epub 2011 Jun 22.

PMID:
21692685
10.

Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.

Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C.

N Engl J Med. 2012 Oct 11;367(15):1417-27. doi: 10.1056/NEJMoa1115050. Erratum in: N Engl J Med. 2012 Nov;367(18):1768.

11.

Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.

Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P.

Clin Cancer Res. 2007 May 15;13(10):2928-35.

12.

Soluble mesothelin-related protein--a blood test for mesothelioma.

Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I.

Lung Cancer. 2005 Jul;49 Suppl 1:S109-11.

PMID:
15950789
13.

[Diagnosis of malignant pleural mesothelioma--thoracoscopic biopsy and tumor marker].

Suzuki K.

Nihon Geka Gakkai Zasshi. 2009 Nov;110(6):333-7. Japanese.

PMID:
19999567
14.

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.

Tsuji S, Tsuura Y, Morohoshi T, Shinohara T, Oshita F, Yamada K, Kameda Y, Ohtsu T, Nakamura Y, Miyagi Y.

Br J Cancer. 2010 Aug 10;103(4):517-23. doi: 10.1038/sj.bjc.6605786. Epub 2010 Jul 13.

15.

Serum and pleural fluid biomarkers for mesothelioma.

Creaney J, Robinson BW.

Curr Opin Pulm Med. 2009 Jul;15(4):366-70. doi: 10.1097/MCP.0b013e32832b98eb. Review.

PMID:
19417672
16.

Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.

Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Müller-Lux A, Gross IM, Wiethege T, Weber A, Raithel HJ, Kraus T, Brüning T.

Arch Toxicol. 2011 Mar;85(3):185-92. doi: 10.1007/s00204-010-0580-2. Epub 2010 Aug 25.

PMID:
20737138
17.

Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.

Filiberti R, Parodi S, Libener R, Ivaldi GP, Canessa PA, Ugolini D, Bobbio B, Marroni P.

Med Oncol. 2013 Jun;30(2):543. doi: 10.1007/s12032-013-0543-6. Epub 2013 Mar 27.

PMID:
23532816
18.

Biomarkers for mesothelioma.

Scherpereel A, Lee YC.

Curr Opin Pulm Med. 2007 Jul;13(4):339-443. Review.

PMID:
17534183
19.

MESOMARK: a potential test for malignant pleural mesothelioma.

Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, Miller MC, Verch T, Allard WJ, Pass HI, Sardesai NY.

Clin Chem. 2007 Apr;53(4):666-72. Epub 2007 Feb 8.

20.

[Diagnosis and staging of malignant pleural mesothelioma].

Sohrab S, Konietzko N.

Pneumologie. 2002 Jun;56(6):382-7. Review. German.

PMID:
12063622
Items per page

Supplemental Content

Write to the Help Desk